Pernix Therapeutics competitorsClear all

Alnylam Pharmaceuticals's top competitors include Celyad and Sorrento Therapeutics.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Celyad
Celyad
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
Sorrento Therapeutics
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Founding Date
Founding Date
2002
Founding Date
2007
Founding Date
2006
Type
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Zug, CH
Windsor And Maidenhead, GB
Locations
Mont-Saint-Guibert, BE HQ
New York, US
Locations
San Diego, US HQ
Employees
Employees
1,06542% increase
Employees
80
Employees
382136% increase
Valuation ($)
Valuation ($)
7.5 b
Valuation ($)
205.7 b
Valuation ($)
368.9 m
Twitter followers
Twitter followers
11 k
Twitter followers
2.1 k
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
32
Number of tweets (last 30 days)
13
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
15.4
Average likes per tweet (last 30 days)
4.8
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
449862
Alexa Website Rank
1093084
Alexa Website Rank
485704

Financial

Revenue (est.)
Revenue (est.)
$74.9m (FY, 2018)
Revenue (est.)
€3.5m (FY, 2017)
Revenue (est.)
$21.2m (FY, 2018)
Cost of goods
Cost of goods
$1.8m (FY, 2018)
Cost of goods
€515k (FY, 2017)
Cost of goods
$7.1m (FY, 2018)
Gross profit
Gross profit
$73.1m (FY, 2018)
Gross profit
€3m (FY, 2017)
Gross profit
$14.1m (FY, 2018)
Net income
Net income
($761.5m) (FY, 2018)
Net income
(€56.4m) (FY, 2017)
Net income
($203.5m) (FY, 2018)

Funding

Total funding raised
Total funding raised
$ 710m
Total funding raised
N/A
Total funding raised
$ 42.6m
For sources of this data, please see the company profile

View company profiles

Celyad
HQ
Mont-Saint-Guibert, BE
Employees
80

Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.

View company
Sorrento Therapeutics
HQ
San Diego, US
Employees
382

Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.

View company